This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Novo Nordisk Makes FORTUNE's List Of '100 Best Companies To Work For' For Third Straight Year

PRINCETON, N.J., Jan. 20, 2011 /PRNewswire/ -- For a third consecutive year, Novo Nordisk, a global healthcare company focusing on diabetes care, has been named to FORTUNE Magazine's prestigious "100 Best Companies to Work For" list for 2011.  Novo Nordisk is ranked 47th in the overall list and is only one of three pharmaceutical/biotechnology companies so honored.  

(Logo: )

"We are extremely honored to be recognized by FORTUNE as one of the '100 Best Companies to Work For'," said Jerzy Gruhn, president of Novo Nordisk Inc. "Everyone in Novo Nordisk has a personal interest in defeating diabetes and supporting patients with hemophilia and other serious conditions. We are so glad to see these efforts noticed for three years in a row."

To pick the "100 Best Companies to Work For," FORTUNE partners with the Great Place to Work Institute to conduct the most extensive employee survey in corporate America. Three hundred eleven companies participated in this year's survey. Two-thirds of a company's score is based on the results of the Institute's Trust Index survey, which is sent to a random sample of employees from each company. The survey asks questions related to their attitudes about management's credibility, job satisfaction, and camaraderie. The other third of the scoring is based on the company's responses to the Institute's Culture Audit, which includes detailed questions about pay and benefit programs and a series of open-ended questions about hiring practices, internal communications, training, recognition programs and diversity efforts.

"At Novo Nordisk, we're all active stewards of our corporate culture.  It's that engagement that allows us to develop and provide medicines of value for people with diabetes and hemophilia," said Jeff Frazier, Vice President of Human Resources. "I appreciate that our efforts to reward our employees for all their great work is recognized by FORTUNE and others in our industry."

About Novo Nordisk

Novo Nordisk is a healthcare company with an 87-year history of innovation and achievement in diabetes care. The company has the broadest diabetes product portfolio in the industry, including the most advanced products within the area of insulin delivery systems. In addition to diabetes care, Novo Nordisk has a leading position within areas such as hemostasis management, growth hormone therapy, and hormone therapy for women.

1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free


Chart of I:DJI
DOW 16,790.19 +13.76 0.08%
S&P 500 1,979.92 -7.13 -0.36%
NASDAQ 4,748.3610 -32.9030 -0.69%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs